FR3060389B1 - ENROBE COMPRISING COMPRISING ULIPRISTAL ACETATE OR ONE OF ITS METABOLITES - Google Patents

ENROBE COMPRISING COMPRISING ULIPRISTAL ACETATE OR ONE OF ITS METABOLITES Download PDF

Info

Publication number
FR3060389B1
FR3060389B1 FR1662926A FR1662926A FR3060389B1 FR 3060389 B1 FR3060389 B1 FR 3060389B1 FR 1662926 A FR1662926 A FR 1662926A FR 1662926 A FR1662926 A FR 1662926A FR 3060389 B1 FR3060389 B1 FR 3060389B1
Authority
FR
France
Prior art keywords
enrobe
metabolites
ulipristal acetate
tablet
ulipristal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1662926A
Other languages
French (fr)
Other versions
FR3060389A1 (en
Inventor
Christine SEGUIN
Suzanne Tran-Fernandes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoire HRA Pharma SAS
Original Assignee
Laboratoire HRA Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire HRA Pharma SAS filed Critical Laboratoire HRA Pharma SAS
Priority to FR1662926A priority Critical patent/FR3060389B1/en
Priority to PCT/FR2017/053735 priority patent/WO2018115743A1/en
Publication of FR3060389A1 publication Critical patent/FR3060389A1/en
Application granted granted Critical
Publication of FR3060389B1 publication Critical patent/FR3060389B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention a pour objet un comprimé enrobé comprenant de l'ulipristal acétate ou un de ses métabolites en tant que principe actif et les utilisations contraceptives et thérapeutiques dudit comprimé.The present invention relates to a coated tablet comprising ulipristal acetate or a metabolite thereof as an active ingredient and the contraceptive and therapeutic uses of said tablet.

FR1662926A 2016-12-20 2016-12-20 ENROBE COMPRISING COMPRISING ULIPRISTAL ACETATE OR ONE OF ITS METABOLITES Active FR3060389B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1662926A FR3060389B1 (en) 2016-12-20 2016-12-20 ENROBE COMPRISING COMPRISING ULIPRISTAL ACETATE OR ONE OF ITS METABOLITES
PCT/FR2017/053735 WO2018115743A1 (en) 2016-12-20 2017-12-20 Coated tablet comprising ulipristal acetate or one of the metabolites thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1662926 2016-12-20
FR1662926A FR3060389B1 (en) 2016-12-20 2016-12-20 ENROBE COMPRISING COMPRISING ULIPRISTAL ACETATE OR ONE OF ITS METABOLITES

Publications (2)

Publication Number Publication Date
FR3060389A1 FR3060389A1 (en) 2018-06-22
FR3060389B1 true FR3060389B1 (en) 2019-05-31

Family

ID=58501547

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1662926A Active FR3060389B1 (en) 2016-12-20 2016-12-20 ENROBE COMPRISING COMPRISING ULIPRISTAL ACETATE OR ONE OF ITS METABOLITES

Country Status (2)

Country Link
FR (1) FR3060389B1 (en)
WO (1) WO2018115743A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
ES2212912B1 (en) 2003-01-22 2005-10-01 Crystal Pharma, S.A. PROCEDURE FOR OBTAINING 17ALFA-ACETOXI-11BETA- (4-N, N-DIMETHYLAMINEPHENYL) -19-NORPREGNA-4,9-DIEN-3,20-DIONA.
US8512745B2 (en) 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
LT2419108T (en) 2009-04-14 2016-12-27 Laboratoire Hra Pharma Method for on-demand contraception
CN102727457B (en) * 2011-04-08 2014-05-28 华润紫竹药业有限公司 A stable ulipristal preparation
FR2997628B1 (en) 2012-11-08 2015-01-16 Hra Pharma Lab CO-MICRONIZATION PRODUCT COMPRISING A SELECTIVE MODULATOR OF PROGESTERONE RECEPTORS
FR2997627B1 (en) 2012-11-08 2015-01-16 Hra Pharma Lab CO-MICRONIZATION PRODUCT COMPRISING ULIPRISTAL ACETATE
FR2999081B1 (en) 2012-12-06 2015-02-27 Hra Pharma Lab SOLID DISPERSION OF A SELECTIVE PROGESTERONE RECEPTOR MODULATOR

Also Published As

Publication number Publication date
FR3060389A1 (en) 2018-06-22
WO2018115743A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
MA49043A (en) STABLE ANTIBODY FORMULATION
BR112018076601A2 (en) oral pharmaceutical formulation, methods for treating a patient, and use of a formulation
MA53356B1 (en) Subcutaneous anti-cd38 antibody formulations and uses thereof
MA40240B1 (en) Heteroaryl compounds of kinase inhibition
BR112015023391A2 (en) formulations comprising anti-egfr drug-antibody conjugate
BR112019025049A2 (en) RINGS 6- 5 CAST AS C5A INHIBITORS
MA45450B1 (en) Anti-cd19 antibody formulations
BR112019001923A2 (en) Spiro-lactam nmda modulators and methods of their use
EA201792590A1 (en) ANTIBODY AGAINST ErbB2 AND MEDICINE AND ITS COMPOSITION, METHOD OF ITS OBTAINING AND ITS APPLICATION
FR3021970B1 (en) ANTIBODY AGAINST GALECTIN 9 AND INHIBITOR OF THE SUPPRESSIVE ACTIVITY OF T REGULATORY LYMPHOCYTES
BR112017014376A2 (en) stable aqueous formulation of vascular endothelial growth antifactor (vegf) antibodies and use
AR098168A1 (en) STABLE FORMULATION OF GLULISINE INSULIN
MX2022001146A (en) Anti-pvrig antibodies formulations and uses thereof.
MA50406B1 (en) Magl pyrazole inhibitors
AR104257A1 (en) RIBOCICLIB TABLET
FR3058059B1 (en) PHARMACEUTICAL COMPOSITION COMPRISING BETA-ELEMENE, LUPEOL AND 2-HYDROXYCINNAMALDEHYDE AND / OR 2'-BENZOYLOXYCINNALMALDEHYDE AND / OR BETA-SITOSTEROL AND / OR CURCUMIN.
MA54052A (en) ANTIBODY FORMULATION
PH12019502676A1 (en) Moisturizing topical preparation
MA43876B1 (en) Pharmaceutical compositions and their uses against lysosomal storage diseases
MA54139A (en) ANTIBODY FORMULATION
MA55033A (en) THERAPEUTIC ANTIBODY FORMULATION
MA53466A (en) STABLE FORMULATION OF ANTI-OSMR ANTIBODIES
MX2019015927A (en) Compositions for drug delivery and methods of use thereof.
EA201990550A1 (en) OPHTHALMIC DRUG INCLUDING THE ASOLIC COMPOUND
MA45718A (en) COMBINATION OF BCL-2 INHIBITOR AND MCL-1 INHIBITOR, ASSOCIATED PHARMACEUTICAL USES AND COMPOSITIONS

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20180622

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8